| Similar Articles |
|---|
 |
Chemistry World
September 25, 2013
Phillip Broadwith |
Nanobody inflammation drug attracts Abbvie Belgian biotech firm Ablynx has agreed a global licensing deal with Abbvie for its nanobody drug candidate ALX-0061.   |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
Chemistry World
October 17, 2014
Phillip Broadwith |
AbbVie backs out of Shire deal AbbVie has recommended its shareholders vote against the deal, and if that happens, the company will pay Shire a break-off fee of $1.6 billion. |
Chemistry World
July 25, 2014
Anthony King |
Pharma firms rush to escape US tax shackles US drug company AbbVie has persuaded Hampshire-based, Irish-headquartered Shire to enter a mega-merger. The enlarged firm will cut its US tax bill. |
Chemistry World
January 6, 2015
Sarah Houlton |
Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion. |
Chemistry World
June 23, 2014
Phillip Broadwith |
Shire fends off AbbVie takeover bid Shire is the latest pharmaceutical company to be targeted for a multi-billion dollar takeover deal from a firm looking to transfer its tax residence outside the US. |
Pharmaceutical Executive
November 1, 2013
Ben Comer |
2014 Pipeline Report: The Sprint to Value Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters. |
